Select Scientific Publications

Nature

CRISPR Screen in Regulatory T Cells Reveals Modulators of Foxp3
Molecular Cell

USP22 Antagonizes p53 Transcriptional Activation by Deubiquitinating Sirt1 to Suppress Cell Apoptosis and Is Required for Mouse Embryonic Development
Cell Discovery

Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1
Science Advances

A Deubiquitination Module Essential for Treg Fitness in the Tumor Microenvironment
Journal of Clinical Investigation

USP22 Drives Tumor Immune Evasion and Checkpoint Blockade Resistance through EZH2-mediated Epigenetic Silencing of MHC-I
Science Advances

Epinephrine Promotes Breast Cancer Metastasis Through a Ubiquitin-specific Peptidase 22-mediated Lipolysis Circuit
iScience (Cell Press)

Ubiquitin-specific Peptidase 22 Controls Integrin-dependent Cancer Cell Stemness and Metastasis

Company Activities & Updates

ExoMira Medicine 5/3/25 ExoMira Medicine 5/3/25

New Involvement

April 2023

ExoMira co-founder Dr. Huiping Liu at Northwestern University was inducted as an elected member to American Society for Clinical Investigation (ASCI).

ExoMira Medicine 5/3/25 ExoMira Medicine 5/3/25

New Ecosystem

April 2023

New Chan Zuckerberg Biohub Chicago will become a neighbor of ExoMira Medicine at the Fulton Labs.

ExoMira Medicine 3/11/19 ExoMira Medicine 3/11/19

Award Received

January 2023

ExoMira co-founders Drs. Huiping Liu and Deyu Fang at Northwestern University received American Cancer Society Cancer Stem Cell Consortium Team Grant (5-year support), congratulations !